The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies
Background: Although infliximab has been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis, the issue of its systemic efficacy and safety in a broader diversity of refractory noninfectious uveitis is debatable. To assess t...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.620340/full |
id |
doaj-b319cb3932ea4d45abf60e9f008d7481 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anji Xiong Anji Xiong Deng Liu Huini Chen Guancui Yang Chen Xiong Yu Shuai Linqian He Zepeng Guo Liangwen Zhang Yuan Yang Beibei Cui Shiquan Shuai Shiquan Shuai |
spellingShingle |
Anji Xiong Anji Xiong Deng Liu Huini Chen Guancui Yang Chen Xiong Yu Shuai Linqian He Zepeng Guo Liangwen Zhang Yuan Yang Beibei Cui Shiquan Shuai Shiquan Shuai The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies Frontiers in Pharmacology infliximab noninfectious uveitis anti-TNF-α uveitis treatment refractory |
author_facet |
Anji Xiong Anji Xiong Deng Liu Huini Chen Guancui Yang Chen Xiong Yu Shuai Linqian He Zepeng Guo Liangwen Zhang Yuan Yang Beibei Cui Shiquan Shuai Shiquan Shuai |
author_sort |
Anji Xiong |
title |
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies |
title_short |
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies |
title_full |
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies |
title_fullStr |
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies |
title_full_unstemmed |
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies |
title_sort |
efficacy and safety of infliximab in refractory noninfectious uveitis: a meta-analysis of observational studies |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-09-01 |
description |
Background: Although infliximab has been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis, the issue of its systemic efficacy and safety in a broader diversity of refractory noninfectious uveitis is debatable. To assess the short-term and relatively long-term efficacy of infliximab in refractory noninfectious uveitis, we performed a systematic review and meta-analysis of observational studies.Methods: PubMed, Cochrane Library, EMBASE, and Wanfang Med Online were systematically searched from January 2005 to March 2020. Two investigators independently assessed eligibility. Data were independently collected by two investigators. The pooled proportions were estimated with patients for intraocular inflammation control and improvement of visual acuity. Pooled proportions with 95% credible intervals were computed. Study homogeneity was investigated using I2 statistics to quantify the percentage of variation across studies. To pool the results, the Mantel–Haenszel fixed-effects or random-effects models were used.Results: Of 2316 studies identified, 16 unique studies with 509 unique participants were included in the meta-analysis. The pooled proportions of intraocular inflammation control reached 92% (95% CI: 87%–98%; I2: 1%; p=0.42) and 95% (95% CI: 93%–97%; I2: 0%; p=0.91) in groups of ≤6- and ≥12-month follow-up durations. During the relatively long follow-up period, the pooled proportions of maintaining visual acuity stable or increasing at least one line reached 99% (95% CI: 96%–100%; I2: 0%; p=0.54) in the involved eyes. The corticosteroid-sparing effect of infliximab was also well demonstrated, with the proportion of corticosteroid-sparing success reaching 85.5% (112/131). Besides, about serious adverse events, 2.6% (13/500) of patients experienced hypersensitivity reactions, 2.4% (12/500) of patients experienced serious infections, 1.8% (9/500) of patients experienced autoimmune diseases, and 0.6% (3/500) of patients experienced neoplasia.Conclusions: This meta-analysis provided evidence that infliximab might be a promising choice in controlling inflammatory activity, gaining visual acuity, and sparing corticosteroid use with relatively few side effects when applied in treating refractory noninfectious uveitis.Systematic Review Registration: [website], identifier [registration number] |
topic |
infliximab noninfectious uveitis anti-TNF-α uveitis treatment refractory |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.620340/full |
work_keys_str_mv |
AT anjixiong theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT anjixiong theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT dengliu theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT huinichen theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT guancuiyang theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT chenxiong theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT yushuai theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT linqianhe theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT zepengguo theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT liangwenzhang theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT yuanyang theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT beibeicui theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT shiquanshuai theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT shiquanshuai theefficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT anjixiong efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT anjixiong efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT dengliu efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT huinichen efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT guancuiyang efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT chenxiong efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT yushuai efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT linqianhe efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT zepengguo efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT liangwenzhang efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT yuanyang efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT beibeicui efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT shiquanshuai efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies AT shiquanshuai efficacyandsafetyofinfliximabinrefractorynoninfectiousuveitisametaanalysisofobservationalstudies |
_version_ |
1717378421328183296 |
spelling |
doaj-b319cb3932ea4d45abf60e9f008d74812021-09-16T05:02:23ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-09-011210.3389/fphar.2021.620340620340The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational StudiesAnji Xiong0Anji Xiong1Deng Liu2Huini Chen3Guancui Yang4Chen Xiong5Yu Shuai6Linqian He7Zepeng Guo8Liangwen Zhang9Yuan Yang10Beibei Cui11Shiquan Shuai12Shiquan Shuai13Department of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaInflammation and Immunology Key Laboratory of Nanchong, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Rheumatology and Immunology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, ChinaInflammation and Immunology Key Laboratory of Nanchong, Nanchong, ChinaBackground: Although infliximab has been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis, the issue of its systemic efficacy and safety in a broader diversity of refractory noninfectious uveitis is debatable. To assess the short-term and relatively long-term efficacy of infliximab in refractory noninfectious uveitis, we performed a systematic review and meta-analysis of observational studies.Methods: PubMed, Cochrane Library, EMBASE, and Wanfang Med Online were systematically searched from January 2005 to March 2020. Two investigators independently assessed eligibility. Data were independently collected by two investigators. The pooled proportions were estimated with patients for intraocular inflammation control and improvement of visual acuity. Pooled proportions with 95% credible intervals were computed. Study homogeneity was investigated using I2 statistics to quantify the percentage of variation across studies. To pool the results, the Mantel–Haenszel fixed-effects or random-effects models were used.Results: Of 2316 studies identified, 16 unique studies with 509 unique participants were included in the meta-analysis. The pooled proportions of intraocular inflammation control reached 92% (95% CI: 87%–98%; I2: 1%; p=0.42) and 95% (95% CI: 93%–97%; I2: 0%; p=0.91) in groups of ≤6- and ≥12-month follow-up durations. During the relatively long follow-up period, the pooled proportions of maintaining visual acuity stable or increasing at least one line reached 99% (95% CI: 96%–100%; I2: 0%; p=0.54) in the involved eyes. The corticosteroid-sparing effect of infliximab was also well demonstrated, with the proportion of corticosteroid-sparing success reaching 85.5% (112/131). Besides, about serious adverse events, 2.6% (13/500) of patients experienced hypersensitivity reactions, 2.4% (12/500) of patients experienced serious infections, 1.8% (9/500) of patients experienced autoimmune diseases, and 0.6% (3/500) of patients experienced neoplasia.Conclusions: This meta-analysis provided evidence that infliximab might be a promising choice in controlling inflammatory activity, gaining visual acuity, and sparing corticosteroid use with relatively few side effects when applied in treating refractory noninfectious uveitis.Systematic Review Registration: [website], identifier [registration number]https://www.frontiersin.org/articles/10.3389/fphar.2021.620340/fullinfliximabnoninfectious uveitisanti-TNF-αuveitis treatmentrefractory |